Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.
Business & Industry
- Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies
- Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
- COVID-19 vaccine AZD1222 clinical trials resumed in the UK
- CureVac expected to receive up to 252 million euros from the German Federal Ministry of Research for further COVID-19 vaccine development and production capacity expansion
- Sinovac reports preliminary Phase I/II results of COVID-19 vaccine in elderly volunteers
Research & Development
- T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
- Designed antiviral proteins inhibit SARS-CoV-2 in the lab
- Progress toward antiviral treatments for COVID-19
- Tiny antibody component highly effective against SARS-COV-2 in animal studies
- Which immune response could cause a vaccine against COVID-19?
- Genome analyses track SARS-CoV-2's early introduction to the US and Europe
- COVID-19 study links strict social distancing to much lower chance of infection
Conferences & Events
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
- Preparing for the new world of drug safety: Embracing cloud and AI
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
Regulatory Affairs
- FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
- FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
- Global regulators commit to cooperate on observational research in the context of COVID-19